Compare
Cardiff Oncology, Inc. vs Prokidney Corp. vs Pluri Inc. vs Inhibrx Biosciences, Inc.
| Latest fiscal year | Cardiff Oncology, Inc. CRDF | Prokidney Corp. PROK | Pluri Inc. PLUR | Inhibrx Biosciences, Inc. INBX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $593.0K | $893.0K | $1.02M | $1.30M |
| Revenue growth (YoY) | -13.2% | n/m | -24.0% | +550.0% |
| Gross margin | n/a | n/a | 44.6% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$45.85M | -$151.61M | -$23.82M | -$140.06M |
| EPS (Diluted) | -$0.69 | n/a | -$2.44 | -$9.04 |
| Operating cash flow | -$37.92M | -$120.12M | -$19.59M | -$129.79M |
| Free cash flow | -$37.97M | -$135.31M | -$20.22M | -$129.82M |
| Cash & equivalents | $17.47M | $108.54M | $3.53M | $124.22M |
| Total assets | $61.88M | $335.57M | $24.88M | $146.48M |
| Total liabilities | $16.50M | $34.78M | n/a | $138.49M |
| Shareholders' equity | $45.39M | -$1.01B | -$23.04M | $7.99M |
| Return on year-end equity | -101.0% | n/a | n/a | n/m |
| Shares outstanding | 68.31M | n/a | 10.82M | 14.58M |
Revenue, most recent five fiscal years
| Fiscal year | Cardiff Oncology, Inc. | Prokidney Corp. | Pluri Inc. | Inhibrx Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $593.0K Ended 2025-12-31 | $893.0K Ended 2025-12-31 | $1.02M Ended 2026-06-30 | $1.30M Ended 2025-12-31 |
| 1 year earlier | $683.0K Ended 2024-12-31 | $76.0K Ended 2024-12-31 | $1.34M Ended 2025-06-30 | $200.0K Ended 2024-12-31 |
| 2 years earlier | $488.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $326.0K Ended 2024-06-30 | $1.80M Ended 2023-12-31 |
| 3 years earlier | $386.0K Ended 2022-12-31 | $0 Ended 2022-12-31 | $287.0K Ended 2023-06-30 | n/a |
| 4 years earlier | $359.0K Ended 2021-12-31 | n/a | $234.0K Ended 2022-06-30 | n/a |